Evaluating the Safety of Immunotherapy in NSCLC Patients With Comorbidities
Combination immunotherapy with nivolumab plus ipilimumab was examined as a first-line therapy for patients with advanced non–small-cell lung cancer. Results were presented at the International Associate for the Study of Lung Cancer 2019 World Conference on Lung Cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news
More News: Cancer | Cancer & Oncology | Conferences | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Study | Yervoy